HR 8205: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

HR 8205 in plain English: This bill reauthorizes through FY2031 federal programs supporting research and development of drugs and therapies for ALS (Lou Gehrig's disease) and other neurodegenerative diseases. It continues grants through the NIH and FDA and maintains a Public-Private Partnership focused on treatment development and regulatory review. The bill also adds new safety reporting requirements and directs the FDA to publish a five-year action plan for fostering ALS drug development.

Stated purpose

This bill extends through 2031 programs that fund research and development of treatments for ALS (Lou Gehrig's disease) and other neurodegenerative diseases, and adds new requirements for safety reporting and FDA planning around those treatments.

Key points

• Reauthorizes NIH grants for ALS drug research for patients not eligible for clinical trials through FY2031
• Reauthorizes FDA grants for developing therapies for ALS and other neurodegenerative diseases through FY2031
• Continues a Public-Private Partnership between the FDA and NIH to support neurodegenerative disease treatment development
• Requires NIH grantees to promptly report serious and unexpected adverse events tied to investigational drugs
• Directs the FDA to publish a five-year plan and a follow-up report on actions to advance ALS drug access and development

Arguments supporters make

• ALS is a fatal disease with few treatment options, and keeping these programs funded gives researchers and patients more time to find and access therapies that could extend or save lives.
• Adding safety reporting requirements and efficacy reviews makes the grant program more rigorous, helping ensure that public funds support drugs that are both safe and showing promise.
• Requiring the FDA to publish a concrete action plan and accountability report pushes the agency to make measurable progress for patients with rare, hard-to-treat neurological diseases.

Arguments opponents make

• Reauthorizing existing programs without a full evaluation of what they have achieved may continue spending on approaches that have not yet produced meaningful results for patients.
• Mandatory reporting and review requirements add administrative burdens on researchers and smaller sponsors, which could slow down or discourage participation in ALS grant programs.
• A five-year FDA action plan is a planning document with no guaranteed outcomes, and critics may argue it creates the appearance of progress without binding the agency to deliver new treatments or approvals.

Tradeoffs

Extending and expanding these programs keeps funding and access alive for a patient population with urgent need, but it commits federal resources through 2031 without a full accounting of past results, and new oversight requirements may add costs and complexity for researchers.

Current status in Congress: Passed both chambers.

NewsClear — neutral news & congressional tracking · Bill of the Week